Compare · AIKI vs CSL
AIKI vs CSL
Side-by-side comparison of AIkido Pharma Inc. (AIKI) and Carlisle Companies Incorporated (CSL): market cap, price performance, sector, and recent activity on the wire.
Summary
- AIKI operates in Consumer Discretionary, while CSL operates in Industrials - the two are in different parts of the market.
- CSL is the larger of the two at $14.72B, about 342.8x AIKI ($42.9M).
- CSL has hit the wire 4 times in the past 4 weeks while AIKI has been quiet.
- CSL has more recent analyst coverage (15 ratings vs 1 for AIKI).
- Company
- AIkido Pharma Inc.
- Carlisle Companies Incorporated
- Price
- $3.61+2.56%
- $360.05-1.08%
- Market cap
- $42.9M
- $14.72B
- 1M return
- -
- +5.85%
- 1Y return
- -
- -4.56%
- Industry
- Specialty Chemicals
- Specialty Chemicals
- Exchange
- NASDAQ
- NYSE
- IPO
- News (4w)
- 0
- 4
- Recent ratings
- 1
- 15
AIkido Pharma Inc.
AIkido Pharma Inc., a biotechnology company, focuses on developing small-molecule anti-cancer therapeutics. Its pipeline of therapeutics includes therapies for pancreatic cancer, acute myeloid leukemia, and acute lymphoblastic leukemia. It is developing DHA-dFdC, a pancreatic drug candidate; and KPC34, a small molecule treatment for acute myeloid leukemia and acute lymphoblastic leukemia. The Company is also developing an antiviral platform that inhibits replication of multiple viruses, including influenza virus, SARS-CoV, MERS-CoV, Ebolavirus, and Marburg virus. It has a license agreement with the University of Texas; and Wake Forest University Health Sciences. The company was formerly known as Spherix Incorporated and changed its name to AIkido Pharma Inc. in March 2021. AIkido Pharma Inc. was founded in 1967 and is based in New York, New York.
Carlisle Companies Incorporated
Carlisle Companies Incorporated operates as a diversified manufacturer of engineered products in the United States, Europe, Asia, Canada, Mexico, the Middle East, Africa, and internationally. It operates through four segments: Carlisle Construction Materials, Carlisle Interconnect Technologies, Carlisle Fluid Technologies, and Carlisle Brake & Friction. The Carlisle Construction Materials segment produces building envelopes for commercial, industrial, and residential buildings, including single-ply roofing products, rigid foam insulations, spray polyurethane foam, architectural metal products, heating, ventilation and air conditioning hardware and sealants, waterproofing products, and air and vapor barrier systems. The Carlisle Interconnect Technologies segment produces wires and cables for the commercial aerospace, military and defense electronics, medical device, industrial, and test and measurement markets. It also offers sensors, connectors, contacts, cable assemblies, complex harnesses, racks, trays, and installation kits, as well as engineering and certification services. The Carlisle Fluid Technologies segment produces engineered liquid products, powder products, sealants and adhesives finishing equipment, and integrated system solutions for spraying, pumping, mixing, metering, and curing of coatings used in the automotive manufacture, general industrial, protective coating, wood, and specialty and automotive refinishing markets. The Carlisle Brake & Friction segment provides duty brakes, and clutch and transmission products for the construction, agriculture, mining, aircraft, on-highway, and other industrial markets. The company sells its products under the Carlisle, Binks, DeVilbiss, Ransburg, BGK, MS Powder, Hawk, Wellman, Thermax, Tri-Star, LHi Technology, Providien, SynTec, Weatherbond, Hunter Panels, Resitrix, Hertalan, Insulfoam, and Velvetouch brands. Carlisle Companies Incorporated was founded in 1917 and is headquartered in Scottsdale, Arizona.
Latest AIKI
- SEC Form SC 13D filed by AIkido Pharma Inc.
- SEC Form SC 13D/A filed by AIkido Pharma Inc. (Amendment)
- Wool Kyle Michael bought $12,996 worth of shares (5,000 units at $2.60) (SEC Form 4)
- Devall Christopher Franklin bought $17,863 worth of shares (7,000 units at $2.55), increasing direct ownership by 30% to 30,033 units (SEC Form 4)
- Wool Kyle Michael was granted 630,050 shares, increasing direct ownership by 77% to 1,448,908 units (SEC Form 4)
- Hayes Anthony bought $140,168 worth of shares (70,000 units at $2.00) (SEC Form 4)
- AIkido Pharma Inc. filed SEC Form 8-K: Leadership Update
- Hayes Anthony bought $8,012 worth of shares (4,000 units at $2.00) (SEC Form 4)
- Wool Kyle Michael bought $8,122 worth of shares (4,000 units at $2.03) (SEC Form 4)
- Devall Christopher Franklin bought $2,278 worth of shares (1,000 units at $2.28), increasing direct ownership by 5% to 23,033 units (SEC Form 4)
Latest CSL
- SEC Form 10-Q filed by Carlisle Companies Incorporated
- Carlisle Companies Incorporated filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Carlisle Companies Reports First Quarter Results
- Carlisle Companies to Announce First Quarter 2026 Results on April 23, 2026
- Amendment: SEC Form SCHEDULE 13G/A filed by Carlisle Companies Incorporated
- Carlisle Companies Publishes 2025 Annual Report
- SEC Form DEFA14A filed by Carlisle Companies Incorporated
- SEC Form DEF 14A filed by Carlisle Companies Incorporated
- SEC Form 4 filed by Director Palmer Sheryl
- SEC Form 4 filed by Director Collins Jonathan R.